Abstract:diabetes-related symptoms or complications. The subsequent management pathway is subject to national and local guidance. There is no universal audit of this pathway, although various observations can be made through a patchy network of clinical databases, local and national. In addition, some information can beinferredfromreturnstotheQualityandOutcomesFramework through which practices receive some payment for diabetes. Nevertheless, given that the main provision of diabetes care resides in primary care, insights into the management of those individuals managed in that sector are surprisingly thin. As part of a rolling audit on outcomes following referral to a consultant-led diabetes service, we monitor different variables to assess the outcome of the referral. However, as part of that audit, we also monitor baseline glycaemic control and microvascular complications of those referred. We report these results as they may inform the debate around the issue of when subjects with diabetes should be referred for a second opinion. All referrals to a consultant-led community clinic between January and June 2009 were collected. This period was chosen to allow time to form an assessment of the outcome of the referral. Baseline characteristics of referred patients were also collected and it is these results we report here (Table 1). The results shown here indicate that onward referral to a specialist service occurs relatively late in the disease pathway of this group of people. Commonly, it becomes apparent that glycaemic control has been poor for many years when the record is fully examined and, as shown, early complications are apparent. An improvement in the HbA1c value of 10.6 mmol ⁄ mol (0.96%) was readily achieved, with an average of 8.4 months follow-up [although, in those already on insulin where the insulin dose or type was adjusted, the HbA1c fall was only 6.0 mmol ⁄ mol (0.56%)]. Is this too little too late? Current thinking on the management of Type 2 diabetes focuses strongly on macrovascular outcomes. It has become clear that any benefit in this area is achieved only after many years of improved glycaemic control [1]. However, the contribution of glycaemic improvement alone, as opposed to blood pressure and lipid lowering, is relatively small [2]. Furthermore, while improvement in microvascular outcomes should not be overlooked [3], improvements in those with established diabetes may not be quite so striking [4,5]. Nevertheless, there is a clear reduction in mortality, with better glycaemic control down to an HbA1c level of 58.5 mmol ⁄ mol (7.5%) [6]. In that context, is it right that referral for escalation of glycaemic therapy in a UK practice should be such a late occurrence, given that glycaemic improvements seem readily achievable ? While clearly a complex debate, it would appear that the pragmatists in primary care have already cast their vote.

Advances in chemotherapy combined with immunotherapy for advanced lung cancer

New progress in immunotherapy of lung cancer

Chemotherapy reinforces anti-tumor immune response and enhances clinical efficacy of immune checkpoint inhibitors

Recent advances in immunotherapy for lung cancer

The prospect of immunotherapy combined with chemotherapy in patients with advanced non-small cell lung cancer: a narrative review

[The elimination of drugs].

The Immunotherapy of Lung Cancer

HbA1c in the diagnosis of diabetes: which cut‐off point?

Immunotherapy-chemotherapy combinations for non-small cell lung cancer: current trends and future perspectives

Recent Advances in Engineered Materials for Immunotherapy‐Involved Combination Cancer Therapy

Efficacy and Mechanism of Combining Radiotherapy and Immunotherapy in Stage IV Non-Small Cell Lung Cancer

Research Advances in Mechanism of Antiangiogenic Therapy Combined with Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer

Combination Immune Checkpoint Inhibitors with Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer: What's Known and What's Next.

Comparative Efficacy and Safety of Immunotherapy Alone and in Combination With Chemotherapy for Advanced Non-small Cell Lung Cancer

Combined treatment of non‐small cell lung cancer using radiotherapy and immunotherapy: challenges and updates

Combined Targeted Therapy and Immunotherapy for Cancer Treatment

Advances in treatment of melanoma with immunotherapy

Combination Strategies of Immunotherapy in Non-Small Cell Lung Cancer: Facts and Challenges

Upfront dose-reduced chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinoma

Clinically approved combination immunotherapy: Current status, limitations, and future perspective